Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Olomouc – page 9

342 clinical trials in Olomouc, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Olomouc at a glance
342
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

342 trials in Olomouc

Open in trial search

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Juvenile idiopathic arthritis

Recruiting

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Aveo Pharmaceuticals Inc.

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Hormone receptor positive breast cancer

Recruiting

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Olomouc

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple cancer types, including metastatic prostate cancer, lung cancer, and colorectal cancer. Research emphasizes innovative treatment approaches and combination therapies.

  • Prostate Cancer Treatment Evaluation
  • Lung Cancer Therapy Development
  • Cervical Cancer Treatment Comparisons

These trials aim to improve survival rates and treatment effectiveness across various cancer types.

02 Cardiovascular and Metabolic Disorders

Studies investigating treatments for heart failure prevention, obesity management, and cardiovascular disease. Focus on innovative therapeutic approaches and combination treatments.

  • Heart Failure Prevention Studies
  • Obesity Treatment Research
  • Cardiovascular Risk Management

Research aims to reduce cardiovascular events and improve patient outcomes.

03 Immunology and Inflammatory Conditions

Clinical investigations targeting Crohn's disease, chronic rhinosinusitis, and other inflammatory conditions. Studies evaluate novel therapeutic approaches and treatment optimization.

  • Inflammatory Bowel Disease Therapy
  • Autoimmune Disease Treatment
  • Infection Management Studies

Research focuses on improving treatment responses and patient quality of life.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.